140
Participants
Start Date
September 8, 2011
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Zidovudine
Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
Liposomal Doxorubicin
Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
Valganiclovir
Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
Rituximab
"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
Standard Therapies
Standard of Care drugs
Cohort 1
Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
RECRUITING
National Institutes of Health Clinical Center, Bethesda
National Cancer Institute (NCI)
NIH